ArticleBMC urology2025
Inflammation-based prognostic markers in renal cell carcinoma: insights from a 15-year experience.
Article in BMC urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Prognostic value of systemic immune-inflammation index in patients with localized and advanced renal cell carcinoma: a systematic review and meta-analysis.Translational andrology and urology · 2026Article
- Association between systemic inflammatory response index and the prognosis of patients with localized and advanced renal cell carcinoma: a systematic review and meta-analysis.Translational andrology and urology · 2026Article
- Incidence, predictors, and prognostic impact of pathological T3a upstaging after robot-assisted partial nephrectomy for clinical T1-T2 renal cell carcinoma.Journal of robotic surgery · 2026Article
- The C-Reactive Protein-Albumin-Lymphocyte (CALLY) Index as an Independent Predictor of Progression and Survival in Metastatic Renal Cell Carcinoma.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionRenal cell carcinoma (RCC) represents nearly 90% of kidney cancers. With improvements in treatment and longer survival, reliable prognostic markers are increasingly important. This study investigated the prognostic value of systemic inflammatory markers and clinicopathological features in RCC patients undergoing nephrectomy. MATERIALS AND
methodsWe retrospectively analyzed 418 patients who underwent radical or partial nephrectomy for RCC between 2009 and 2024. Preoperative hematologic markers, including neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), lymphocyte-to-monocyte ratio (LMR), systemic inflammatory response index (SIRI), and systemic immune-inflammation index (SII), were evaluated. Their associations with overall survival (OS) and recurrence-free survival (RFS) were assessed using survival analyses and multivariate Cox regression.
resultsThe cohort had a median age of 60.5 years and a median follow-up of 72.3 months. Elevated NLR, PLR, SIRI, SII, and reduced LMR were associated with worse OS and RFS. On multivariate analysis, age > 64.5 years, higher tumor grade, NLR ≥ 2.93, and LMR < 3.67 independently predicted poorer OS.
conclusionsSimple, routinely available preoperative inflammatory markers, particularly NLR and LMR, may serve as useful predictors of survival in RCC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.